Breakthrough T1D®
Formerly JDRF

## Stage 2 T1D Disease-Modifying Therapy Clinical Trials (Multi-site)

| | | |
|---|---|---|
| DRUG | **A Study of Baricitinib for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY)**<br>AGES 1–35<br>STAGE 2 T1D (AT LEAST 2 AUTOANTIBODIES)<br>ORAL PILL | |
| DRUG | **Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG (ASCEND T1D)**<br>AGES 4–34<br>STAGE 2 T1D (AT LEAST 2 AUTOANTIBODIES)<br>IV INFUSIONS | |

## Stage 2 T1D Disease-Modifying Therapy Clinical Trials (Single site)

| | | |
|---|---|---|
| DRUG | **GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab (GLP-TEP)**<br>AGES 12–50<br>STAGE 2 T1D (AT LEAST 2 AUTOANTIBODIES)<br>ORAL PILL<br>VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN | |

## Stage 3 T1D Disease-Modifying Therapy Clinical Trials (Multi-site)

| | | |
|---|---|---|
| DRUG | **A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)**<br>AGES 1–35<br>WITHIN 100 DAYS OF DIAGNOSIS<br>ORAL PILL | |


© 2026 Breakthrough T1D. All rights reserved.

Breakthrough T1D®
Formerly JDRF

| Stage 3 T1D<br>Disease-Modifying Therapy Clinical Trials (Multi-site) | | |
|---|---|---|
| DRUG | **A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes (βETA PRESERVE)**<br>AGES 1–25<br>WITHIN 8 WEEKS OF DIAGNOSIS<br>IV INFUSION | |
| DRUG | **Precision Administration of Anti-thymocyte Globulin With or Without Verapamil**<br>AGES 6–35<br>WITHIN 100 DAYS OF DIAGNOSIS<br>IV INFUSIONS AND ORAL PILL | |
| DRUG | **Rezpegaldesleukin in New Onset Type 1 Diabetes Mellitus**<br>AGES 18–45 (AGES 8–17 OPENING IN STAGES)<br>WITHIN 100 DAYS OF DIAGNOSIS<br>INJECTIONS | |
| DRUG | **A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (WAVE T1D)**<br>AGES 9–20<br>WITHIN 6 MONTHS OF DIAGNOSIS<br>IV INFUSION, THEN INJECTION OR ORAL PILL | |


© 2026 Breakthrough T1D. All rights reserved.

| | | |
|---|---|---|
| DRUG | **CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)**<br>AGES 12–35<br>DIAGNOSED FOR LESS THAN 6 MONTHS<br>IV INFUSIONS | |
| DRUG | **SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes (SAFEGUARD)**<br>PART A AGES 15–40<br>PART B AGES 5–40<br>WITHIN 100 DAYS OF DIAGNOSIS<br>IV INFUSION | |
| DRUG | **Denosumab for Type 1 Diabetes**<br>FEMALES AGES 18–50<br>MALES AGES 21–50<br>DIAGNOSED FOR ≥ 12 MONTHS BUT ≤ 5 YEARS<br>INJECTION | |
| DRUG | **A Study of GNTI-122 in Adults Recently Diagnosed With T1D (POLARIS)**<br>AGES 18–55<br>WITHIN 180 DAYS OF DIAGNOSIS<br>MUST BE HLA-DRB1*04:01 POSITIVE<br>SINGLE DOSE | |
| DRUG | **Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus**<br>AGES 18–50<br>PART A: DIAGNOSED WITHIN THE LAST 20 YEARS<br>PART B: DIAGNOSED WITHIN 1–10 YEARS<br>PART C: DIAGNOSED ≤ 1 YEAR<br>INJECTION | |


© 2026 Breakthrough T1D. All rights reserved.

Breakthrough T1D®
Formerly JDRF

# Trial Tools and Contact Information

| | | |
|---|---|---|
|  TRIAL TOOLS | **Clinical Trials Connection Tool**<br>Match to a clinical trial in 60 seconds | |
|  CONTACT INFO | **Clinical Trial Education Volunteers**<br>Your key to participation!<br>Connect with a local volunteer trained to answer any questions you may have. | |


© 2026 Breakthrough T1D. All rights reserved.